Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
Bylvay missed the study’s primary objective of showing an improvement in native liver survival rates compared to placebo.
The Source
TWSJ
Tech
It’s the Deadliest Room in the House—Especially for Seniors
TWSJ·1d ago·3 min read
Tech
EU Says TikTok’s Accounts for Minors May Breach Bloc’s Digital Rulebook
TWSJ·1h ago·3 min read
Business
Global Goods Trade Rose Again In May, But New Tariffs Loom
TWSJ·56m ago·3 min read
World News
Ex-Wife in South Korea’s ‘Divorce of the Century’ Awarded $645 Million
TWSJ·49m ago·3 min read
Related
On this beat
Health
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
TWSJ·1h ago·3 min read
Health
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
TWSJ·4h ago·3 min read
Health
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
TWSJ·5h ago·3 min read
Health
An outbreak of cyclosporiasis that’s sickened thousands shouldn’t prevent you from enjoying a Caesar salad—if you take the right precautions
TWSJ·22h ago·3 min read